Hospital
Yavapai Community Hospital Association
Yavapai Community Hospital Association was paid $66.19M by Medicaid between Jan 2018 and Dec 2024, across 317 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoYAVAPAI COMMUNITY HOSPITAL ASSOCIATION
PRESCOTT, AZ 86301
PRESCOTT, AZ 86301
33aNPI1902897820assigned 10/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$66.19M
24GClaims1,488,309
24DCodes billed317
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#5 of 78
Median peer was paid$12.21M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 226,009 | $9.94M | |
| 2019 | 239,417 | $10.52M | |
| 2020 | 201,379 | $9.39M | |
| 2021 | 204,254 | $9.39M | |
| 2022 | 203,593 | $9.55M | |
| 2023 | 233,689 | $9.76M | |
| 2024incomplete | 179,968 | $7.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 53,895 | 49,142 | $12.28M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 50,689 | 44,510 | $11.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 21,270 | 18,763 | $7.99M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 12,103 | 11,218 | $7.46M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 4,810 | 4,544 | $2.36M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 12,879 | 11,813 | $2.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 15,231 | 14,057 | $2.07M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 3.0% | 3,755 | 3,531 | $2.00M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 3.0% | 2,167 | 2,029 | $1.99M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.6% | 1,864 | 1,707 | $1.73M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.9% | 514 | 472 | $1.26M |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 3,391 | 3,176 | $1.13M |
305 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 4,952 | $1.13M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 2,186 | $746K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,477 | $605K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 16,412 | $460K |
| 97597 | <1% | 5,232 | $383K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13,018 | $364K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,171 | $363K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,518 | $361K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,894 | $330K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 387 | $294K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,494 | $271K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,979 | $259K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,203 | $258K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,265 | $247K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,060 | $247K |
| 93971 | <1% | 3,807 | $199K | |
| 80053 | Comprehensive metabolic panel | <1% | 78,204 | $196K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,840 | $194K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,541 | $194K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 810 | $193K |
| 71250 | <1% | 2,619 | $185K | |
| 93970 | <1% | 1,939 | $178K | |
| 77080 | <1% | 1,815 | $176K | |
| 76641 | <1% | 2,552 | $174K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,240 | $168K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,180 | $163K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,136 | $145K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,707 | $133K |
| 72110 | <1% | 1,153 | $127K | |
| 97162 | <1% | 2,382 | $120K | |
| G0378 | Hospital observation service, per hour | <1% | 6,293 | $117K |
| 78227 | <1% | 256 | $114K | |
| 70486 | <1% | 1,423 | $107K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,152 | $103K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,496 | $96K |
| 72141 | <1% | 720 | $96K | |
| 72100 | <1% | 3,736 | $93K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 351 | $93K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 34,590 | $91K |
| 73562 | <1% | 4,082 | $87K | |
| 73630 | <1% | 4,156 | $86K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 103 | $82K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,151 | $81K |
| 76536 | <1% | 1,172 | $80K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 44,168 | $79K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,799 | $78K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 220 | $77K |
| 93880 | <1% | 1,036 | $71K | |
| 76770 | <1% | 978 | $70K | |
| 12002 | <1% | 742 | $64K | |
| 73030 | <1% | 3,646 | $62K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 34,377 | $60K |
| 72072 | <1% | 1,463 | $57K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 884 | $56K |
| 76830 | Ultrasound, transvaginal | <1% | 1,858 | $54K |
| 74018 | <1% | 2,191 | $53K | |
| 73221 | <1% | 353 | $51K | |
| 73130 | <1% | 3,309 | $47K | |
| 77065 | Tomosynthesis, mammo | <1% | 671 | $44K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,704 | $43K |
| 94060 | <1% | 130 | $43K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 256 | $41K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,932 | $40K |
| 93017 | <1% | 2,116 | $39K | |
| 93798 | <1% | 519 | $38K | |
| 73610 | <1% | 3,417 | $37K | |
| 73110 | <1% | 2,601 | $36K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,917 | $35K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 636 | $31K |
| 74178 | <1% | 138 | $31K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,266 | $30K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,340 | $29K |
| J0897 | Injection, denosumab, 1 mg | <1% | 87 | $28K |
| 73502 | <1% | 2,226 | $26K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,885 | $26K |
| 86900 | <1% | 3,803 | $24K | |
| 12001 | <1% | 1,208 | $23K | |
| 87640 | <1% | 987 | $22K | |
| 71271 | <1% | 398 | $22K | |
| 72040 | <1% | 1,213 | $21K | |
| 43235 | <1% | 62 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,168 | $19K |
| 10060 | <1% | 547 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,344 | $19K |
| 72050 | <1% | 334 | $19K | |
| 73080 | <1% | 1,533 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,513 | $16K |
| 70491 | <1% | 41 | $15K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,692 | $15K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,996 | $15K |
| 88341 | <1% | 86 | $15K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 469 | $14K |
| 80061 | Lipid panel | <1% | 2,360 | $13K |
| 73523 | <1% | 134 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 199 | $10K |
| 80305 | <1% | 12,414 | $10K | |
| 88342 | <1% | 2,340 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 83,271 | $9K |
| 70498 | <1% | 26 | $9K | |
| 76882 | <1% | 165 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,799 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,643 | $8K |
| 97166 | <1% | 560 | $8K | |
| 73590 | <1% | 1,136 | $8K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $8K |
| 73564 | <1% | 112 | $7K | |
| 73700 | <1% | 28 | $7K | |
| 71101 | <1% | 289 | $7K | |
| 59025 | Fetal non-stress test | <1% | 537 | $7K |
| 93925 | <1% | 48 | $7K | |
| 72131 | <1% | 29 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 408 | $6K |
| C1769 | Guide wire | <1% | 1,166 | $6K |
| 74019 | <1% | 336 | $6K | |
| 64400 | <1% | 14 | $5K | |
| 84484 | <1% | 21,964 | $5K | |
| 73140 | <1% | 566 | $4K | |
| 76870 | <1% | 176 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $4K |
| 87070 | <1% | 2,664 | $4K | |
| C1729 | Catheter, drainage | <1% | 782 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,968 | $4K |
| 73090 | <1% | 745 | $4K | |
| 76801 | <1% | 175 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,713 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,490 | $3K |
| 76983 | <1% | 53 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 768 | $3K |
| 90715 | <1% | 2,763 | $3K | |
| 97802 | <1% | 81 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,296 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,791 | $3K |
| 82731 | <1% | 93 | $3K | |
| 76981 | <1% | 28 | $3K | |
| 83880 | <1% | 5,100 | $2K | |
| 87631 | <1% | 2,729 | $2K | |
| 96376 | <1% | 7,967 | $2K | |
| 73560 | <1% | 83 | $2K | |
| 84702 | <1% | 2,931 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,010 | $2K |
| 93922 | <1% | 85 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,626 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 47,704 | $2K |
| J3490 | Unclassified drugs | <1% | 16,311 | $2K |
| 83690 | <1% | 26,963 | $2K | |
| 95816 | <1% | 12 | $2K | |
| 29125 | <1% | 573 | $2K | |
| 80074 | <1% | 12 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 17,888 | $2K |
| 88304 | <1% | 518 | $2K | |
| 81003 | <1% | 56,050 | $2K | |
| 87040 | <1% | 4,722 | $1K | |
| 12011 | <1% | 206 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,898 | $1K |
| 82570 | <1% | 169 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 36,101 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,157 | $1K |
| 85730 | <1% | 14,381 | $1K | |
| 87186 | <1% | 4,445 | $922.87 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,084 | $909.62 |
| 74220 | <1% | 13 | $897.87 | |
| 80320 | <1% | 11,722 | $780.21 | |
| 82550 | <1% | 5,991 | $745.28 | |
| 97116 | <1% | 691 | $725.34 | |
| 73020 | <1% | 13 | $580.78 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,445 | $536.74 |
| 87075 | <1% | 318 | $533.20 | |
| 76982 | <1% | 375 | $530.88 | |
| 83605 | <1% | 4,270 | $530.31 | |
| 85380 | <1% | 7,092 | $528.33 | |
| 85610 | <1% | 19,293 | $525.17 | |
| 29515 | <1% | 141 | $498.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,975 | $486.35 |
| 83735 | <1% | 14,879 | $427.15 | |
| 82728 | <1% | 413 | $404.34 | |
| 86140 | <1% | 3,351 | $372.19 | |
| 84145 | <1% | 2,555 | $356.64 | |
| 84703 | <1% | 5,928 | $331.48 | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,100 | $312.42 |
| 86803 | <1% | 12 | $291.59 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,364 | $249.62 |
| 82565 | <1% | 4,055 | $245.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,990 | $242.65 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,364 | $242.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,368 | $229.21 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 11,554 | $221.63 |
| 86901 | <1% | 3,971 | $216.38 | |
| 82962 | <1% | 11,088 | $198.56 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,879 | $194.72 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,128 | $165.28 |
| 73060 | <1% | 12 | $155.94 | |
| 74022 | <1% | 58 | $155.39 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,166 | $145.09 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 397 | $141.92 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,721 | $140.23 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,065 | $133.67 |
| 82607 | <1% | 196 | $122.13 | |
| 85652 | <1% | 2,781 | $118.83 | |
| 87046 | <1% | 140 | $117.06 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 207 | $100.85 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,567 | $89.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,171 | $87.04 |
| 87450 | <1% | 76 | $82.78 | |
| 87081 | <1% | 12 | $82.55 | |
| 86592 | <1% | 13 | $74.35 | |
| 89055 | <1% | 28 | $73.73 | |
| 94726 | <1% | 55 | $70.66 | |
| 82746 | <1% | 13 | $70.31 | |
| 84481 | <1% | 17 | $69.56 | |
| 87205 | <1% | 3,061 | $67.66 | |
| 73552 | <1% | 26 | $65.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,165 | $62.83 |
| 86850 | <1% | 2,339 | $59.13 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,714 | $57.57 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,382 | $50.00 |
| 84439 | <1% | 1,370 | $49.41 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,926 | $47.18 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 250 | $42.32 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 280 | $42.01 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,513 | $41.54 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,579 | $40.71 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,510 | $37.34 |
| 80164 | <1% | 46 | $35.98 | |
| 82140 | <1% | 92 | $35.38 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,067 | $34.74 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,522 | $32.25 |
| 87210 | <1% | 77 | $30.87 | |
| 86780 | <1% | 144 | $29.53 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,852 | $29.24 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 374 | $29.18 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 991 | $28.41 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,647 | $28.37 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 868 | $26.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,162 | $25.55 |
| Q4131 | Epifix or epicord, per square centimeter | <1% | 31 | $25.39 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 794 | $25.20 |
| 86308 | <1% | 308 | $24.76 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,630 | $21.61 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 811 | $20.25 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 25 | $20.20 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 343 | $19.30 |
| 82010 | <1% | 273 | $17.16 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 988 | $16.75 |
| 87077 | <1% | 536 | $12.74 | |
| 84100 | <1% | 1,316 | $12.27 | |
| 84156 | <1% | 61 | $11.13 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 285 | $9.00 |
| 84550 | <1% | 183 | $8.72 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 155 | $5.80 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 247 | $3.29 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 426 | $0.55 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 359 | $0.13 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,902 | $0.10 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 283 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 1,315 | $0.00 |
| 87045 | 0% | 75 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 658 | $0.00 |
| 77062 | 0% | 391 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 434 | $0.00 |
| 99453 | 0% | 47 | $0.00 | |
| 87641 | 0% | 987 | $0.00 | |
| 87427 | 0% | 75 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 198 | $0.00 |
| 84112 | 0% | 91 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 257 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 27 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 96 | $0.00 |
| 94729 | 0% | 85 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 158 | $0.00 |
| 83540 | 0% | 44 | $0.00 | |
| 51702 | 0% | 27 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 52 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 96367 | 0% | 19 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 79 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 30 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 12 | $0.00 |
| 29105 | 0% | 12 | $0.00 | |
| 99152 | 0% | 38 | $0.00 | |
| 77061 | 0% | 13 | $0.00 | |
| 80329 | 0% | 4,808 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 1,078 | $0.00 |
| J7131 | Hypertonic saline solution, 1 ml | 0% | 125 | $0.00 |
| 76377 | 0% | 412 | $0.00 | |
| 94761 | 0% | 525 | $0.00 | |
| 87428 | 0% | 91 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 325 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 59 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 309 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 48 | $0.00 |
| 86701 | 0% | 15 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 113 | $0.00 |
| J2805 | Injection, sincalide, 5 micrograms | 0% | 141 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 184 | $0.00 |
| 83615 | 0% | 12 | $0.00 | |
| 88307 | 0% | 28 | $0.00 | |
| 87493 | 0% | 13 | $0.00 | |
| 84132 | 0% | 30 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 105 | $0.00 |
| 83550 | 0% | 16 | $0.00 | |
| 87807 | 0% | 36 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 19 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 22 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 24 | $0.00 |
| 87449 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICE, MATT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Yavapai Regional Medical Center Physician Care LLC | Prescott Valley, AZ | $3.69M |
| Yavapai Regional Medical Center Physician Care LLC | Prescott, AZ | $663K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.